Guangzhou Innogen Pharmaceutical Group Co Ltd

02591

Company Profile

  • Business description

    Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.

  • Contact

    No. 2 Tengfei Second Street
    Room 409, Building H Self-numbered Creative Building
    China-Singapore Guangzhou Knowledge City
    Huangpu District, Guangdong Province
    Guangzhou
    CHN

    https://www.innogenpharm.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    96

Stocks News & Analysis

stocks

Apple earnings: Strong performance overpowers headwinds, and we raise our FVE

Our view of Apple shares.
stocks

Coles is winning the supermarket wars but is Woollies the better long-term opportunity?

Our view after first quarter sales updates.
stocks

Microsoft earnings: Strong, including Azure, but overall guidance is in line

We think Microsoft stock is moderately undervalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,182.5024.000.26%
CAC 408,105.8615.21-0.19%
DAX 4024,147.54189.240.79%
Dow JONES (US)47,381.71181.16-0.38%
FTSE 1009,706.4810.77-0.11%
HKSE26,158.36251.710.97%
NASDAQ23,877.27152.310.64%
Nikkei 22552,411.341,085.732.12%
NZX 50 Index13,556.307.980.06%
S&P 5006,845.985.780.08%
S&P/ASX 2008,894.8036.200.41%
SSE Composite Index3,976.5221.730.55%

Market Movers